Studies of biomarker responses to intervention with riboflavin: a systematic review
Studies of biomarker responses to intervention with riboflavin: a systematic review
复制标题
DOI：
10.3945/ajcn.2009.27230b
复制
发表时间：
2009-06-01
影响因子：
7.1
通讯作者：
Strain, J. J.
中科院分区：
文献类型：
--
作者：
Hoey, Leane;McNulty, Helene;Strain, J. J.
背景资料：全国调查数据的红细胞谷胱甘肽还原酶活化系数（EGRac）表明，次优核黄素状态可能是一个问题，在所有人口年龄组，但截止缺乏是有争议的。此外，不同生物标志物的核黄素状态的有效性还没有得到严格的evaluated.Objective：我们的目的是评估不同生物标志物的核黄素状态的有效性，通过对已发表的核黄素补充trials.Design：我们构建了我们的搜索策略，在奥维德MEDLINE，EMBASE（奥维德），和科克伦数据库;正式的纳入和排除标准;数据提取;有效性评估;结果：18项补充研究报告了多达14种生物标志物。有足够的数据表明EGRac（14项研究）和基础谷胱甘肽还原酶活性（5项研究）是核黄素摄入量改变的有效生物标志物（P < 0.00001），尽管观察到亚组分析无法解释的实质异质性（I-2 > 66%）。血浆总同型半胱氨酸是不是一个有效的生物标志物的核黄素状态在一般人群中，但一些证据表明其潜在的有用性，特别是在那些纯合子的一个共同的多态性在MTHFR gene.Conclusions：证据表明，EGRac是一个有效的生物标志物的核黄素摄入量的变化，在人群中严重到正常的基线状态。需要对健康人群进行研究，比较不同年龄，性别和MTHFR基因型组对低剂量补充剂的反应，以提供针对不同人群亚组的膳食核黄素建议的证据。还需要进一步研究EGRac的替代生物标志物。美国临床营养杂志2009; 89（增刊）：1960 S-80 S。
Background: National survey data of erythrocyte glutathione reductase activation coefficient (EGRac) indicate that suboptimal riboflavin status may be a problem in all population age groups, but the cutoff for deficiency is controversial. In addition, the effectiveness of different biomarkers of riboflavin status has not been critically evaluated.Objective: We aimed to assess the effectiveness of different biomarkers of riboflavin status through a systematic review of published riboflavin supplementation trials.Design: We structured our search strategy on Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases; formal inclusion and exclusion criteria; data extraction; validity assessment; and meta-analysis.Results: Eighteen supplementation studies reporting up to 14 biomarkers were included. Sufficient data were available to show that EGRac (14 studies) and basal glutathione reductase activity (5 studies) were effective biomarkers of altered riboflavin intake (P < 0.00001), although substantial heterogeneity (I-2 > 66%) that could not be explained by the subgroup analysis was observed. Plasma total homocysteine was not an effective biomarker of riboflavin status in the general population, but some evidence identified its potential usefulness specifically in those homozygous for a common polymorphism in the MTHFR gene.Conclusions: The evidence suggests that EGRac is an effective biomarker of a change in riboflavin intake in populations with severe-to-normal baseline status. Studies of healthy populations that compare the response to low-dose supplementation among different age, sex, and MTHFR genotype groups are required to provide evidence for generating dietary riboflavin recommendations specific to different population subgroups. Further research into alternative biomarkers to EGRac is also required. Am J Clin Nutr 2009; 89 (suppl): 1960S-80S.